The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

We have reached the "Fartcoin" stage of the market cycle - Fartcoin is only the latest memecoin; there have been other memecoins before. We have thought quite a bit about cryptocurrencies, and for the ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...